Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
about
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancerPharmacology of iron transportSmall molecule compounds targeting the p53 pathway: are we finally making progress?The role of p53 in cancer drug resistance and targeted chemotherapyγ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizersQuantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugsG2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone CompoundStructure-antiproliferative activity studies on l-proline- and homoproline-4-N-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(ii), palladium(ii) and copper(ii) complexes.Copper(ii) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells.Design, synthesis and bioactivity of N-glycosyl-N'-(5-substituted phenyl-2-furoyl) hydrazide derivatives.Iron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones.Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate--ZMC1.Advances in iron chelation: an update.Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanismAllele-specific p53 mutant reactivation.Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats.Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.Novel immunosuppressive agent caerulomycin A exerts its effect by depleting cellular iron contentSynthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore.Strong effect of copper(II) coordination on antiproliferative activity of thiosemicarbazone-piperazine and thiosemicarbazone-morpholine hybrids.Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study.Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers.A novel copper(II) complex identified as a potent drug against colorectal and breast cancer cells and as a poison inhibitor for human topoisomerase IIα.Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trappingImpact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance CircumventionImaging PEG-like nanoprobes in tumor, transient ischemia, and inflammatory disease modelsAnticancer activity of metal complexes: involvement of redox processes.Metallosupramolecular grid complexes: towards nanostructured materials with high-tech applications.Understanding the metabolism of the anticancer drug Triapine: electrochemical oxidation, microsomal incubation and in vivo analysis using LC-HRMS.Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53.Synthesis and Evaluation of New Benzodioxole- Based Thiosemicarbazone Derivatives as Potential Antitumor Agents.Cytotoxic activity of expanded coordination bis-thiosemicarbazones and copper complexes thereof.
P2860
Q26800059-D49DF1E8-C0AF-4D6B-A5A3-E7361738E857Q27009387-1CD56EBF-8DB8-4428-BE01-71003098B7ECQ27027835-C3ED0BCB-FE87-4EB8-8E7F-99361B371505Q28072553-D373939E-32C5-45E6-8A52-44498ABE9E5DQ28480920-79F6EA3C-9306-4983-945E-0932882FEDD3Q28539989-0EB5F807-CBEC-4202-A7B4-5DDE323D330DQ28547905-718E589B-0F58-4B83-B8FD-0BA109C819E3Q31119195-6D951325-139A-48A8-90A2-583242A02E72Q31172464-553A377A-430C-455E-88AE-99AA6D4485A0Q33580773-EE121926-E50E-4A07-A91E-3C2FEE4AB2E7Q33636546-5F71F3AB-149D-4002-ABDE-B59D3512B300Q33728282-C5DE21B9-2218-4E20-9218-6B79B7892B09Q33827191-96646A1D-E779-4F54-9DA7-D9118D192C63Q34174307-3C6F1B0E-08AE-44B4-9512-1DAD156129CFQ34178561-B56B40CB-30A4-4A6D-9B3B-A46DD52A8ED9Q34459006-21FD7A77-865A-4060-A821-88D0F10ED3ABQ34619139-5481B954-D6BF-405B-8933-7FC6314C60A5Q34638529-09FC9F12-7344-41C7-9446-47E2F0755AD8Q35047321-68A3F665-C9A6-4E40-860C-5CD0CCB0F2FEQ35348485-43FE69E1-EAFD-4C4F-9F73-25B6F75DB612Q35484363-140A6EE2-F439-4857-A78D-FFCC9F0ED58DQ35531853-0045F779-F078-48B8-93EC-ABFCC3B6A8E6Q35610388-1EA8B1D9-3F71-45C5-80E3-31ED7B58631BQ35657936-9F55F042-F891-4200-891E-8E7FBDBB3CB1Q36025551-1D3E0194-6415-4870-A2D7-D3A70047B0F1Q36278270-1D08581E-A5D8-465D-B682-A065008FF22DQ36440601-C8A8E9A1-8C4F-407E-81ED-76AD0CFDF4BEQ36557412-361C596B-CF9A-46ED-A19E-2F5195F1CB45Q36568904-97619178-2905-4C1C-A03F-F12DDA839233Q36568908-ADECC1E3-A68C-40F0-80DE-2930B4825AF8Q36618876-40B48BB3-2990-4D14-B19C-9A4037F23BB4Q36844094-9CA3705A-3A76-4C5E-A411-E2CEB907B8E6Q37138681-D9FADC64-5A40-4F64-A6FC-8BF3C62E5FBAQ37735698-37DF1285-A16B-4934-ACDC-86CFFD88388DQ37833099-3410CAF0-F7DC-4EEF-ACFF-ABE1E59235B7Q38116411-59DECE71-85DE-48C8-AB1B-0EB2A0E1D33AQ38660736-38874E6A-4A39-4D46-9823-2D7CFCEECF4BQ38711481-26238F7C-1B00-4855-9D5E-407FFA3E76B3Q38729281-F4C627C3-F5D6-4A39-900C-DF1F35908B50Q38744982-43F0AD3B-02CB-4AD7-BF4B-2E9C153669BE
P2860
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thiosemicarbazones from the ol ...... cleotide reductase inhibitors.
@en
Thiosemicarbazones from the ol ...... cleotide reductase inhibitors.
@nl
type
label
Thiosemicarbazones from the ol ...... cleotide reductase inhibitors.
@en
Thiosemicarbazones from the ol ...... cleotide reductase inhibitors.
@nl
prefLabel
Thiosemicarbazones from the ol ...... cleotide reductase inhibitors.
@en
Thiosemicarbazones from the ol ...... cleotide reductase inhibitors.
@nl
P2093
P50
P356
P1476
Thiosemicarbazones from the ol ...... ucleotide reductase inhibitors
@en
P2093
Aritee R Siafakas
Christian Stefani
Patric J Jansson
P304
P356
10.1021/JM900552R
P407
P50
P577
2009-09-01T00:00:00Z